HCV and Cardiovascular Disease

Epidemiological data demonstrate a link between HCV infection and cardiovascular disease, whereas treatment studies suggest viral eradication may lower the risk for cardiovascular morbidity and ...

Treating Rheumatic Manifestations of Hepatitis C Virus

Patients with HCV are at risk for several extrahepatic sequelae. Find out what they are and the new treatment options for managing HCV in patients ...

Managing HCV in Liver Transplant Candidates and Recipients

Expert insight from Leslie B. Lilly, MD, FRCPC, medical director of GI Transplantation from the Toronto General Hospital in Canada, about direct-acting antivirals in the ...

HCV and Type 2 Diabetes

Hepatitis C virus infection may increase the risk for type 2 diabetes, but whether a causal relationship exists is unclear. Screening for type 2 diabetes ...

EASL Condemns Cochrane Review of DAA-Based Treatment for HCV

The European Association for the Study of the Liver raises concerns over Cochrane Review of direct acting antivirals for hepatitis C virus.

Latest News

FDA Announces Orphan Drug Designation for HDV Drug

FDA Announces Orphan Drug Designation for HDV Drug

The Orphan Drug Designation Program offers orphan status to biologics and drugs that are safe and effective for rare diseases; also for prevention use.

HCC Risk After HCV Direct-Acting Antiviral Treatment

HCC Risk After HCV Direct-Acting Antiviral Treatment

The occurrence or recurrence risk for hepatocellular carcinoma is unclear after direct-acting antiviral agents and interferon based therapy.

Three-Part Strategy Announced for Hepatitis A Outbreak

Three-Part Strategy Announced for Hepatitis A Outbreak

A 3-part strategy was announced to combat the hepatitis A outbreak in San Diego, California.

DAAs Effective for HCV in Patients With Thalassemia

DAAs Effective for HCV in Patients With Thalassemia

Researchers compared the safety and efficacy of sofosbuvir plus ledipasvir vs pegylated interferon and ribavirin for 12 weeks in patients with thalassemia major and hepatitis C virus genotype 1 or 4.

Hepatitis B, Hepatitis C, HIV More Common in Severe Mental Illness

Hepatitis B, Hepatitis C, HIV More Common in Severe Mental Illness

HIV, hepatitis B, and hepatitis C infections are more prevalent among patients with severe mental illness than in the general population.

CDC: More Interventions Needed to Aid HCV Elimination Program in Country of Georgia

CDC: More Interventions Needed to Aid HCV Elimination Program in Country of Georgia

More interventions are needed to meet the target of hepatitis C virus elimination in the country of Georgia, defined as a 90% reduction in prevalence by 2020.

AAP: Hepatitis B Vaccine Should Be Given Within 24 Hours of Birth

AAP: Hepatitis B Vaccine Should Be Given Within 24 Hours of Birth

The first dose of the hepatitis B vaccine should be given within the first 24 hours of life.

HCV Treatment Administered by Non-Specialists Safe, Effective

HCV Treatment Administered by Non-Specialists Safe, Effective

Non-specialists, including primary care providers and nurse practitioners, safely and effectively administer direct-acting antiviral therapy for hepatitis C virus to patients seen in FQHCs.

FDA Expands Epclusa® Indication for HCV/HIV Co-infection

FDA Expands Epclusa® Indication for HCV/HIV Co-infection

The FDA has approved an expanded indication for Epclusa to include the use of this once-daily single tablet regimen in patients co-infected with chronic hepatitis C virus and HIV.

New WHO Guidelines for Hepatitis B Virus Vaccine

New WHO Guidelines for Hepatitis B Virus Vaccine

The World Health Organization published a position paper with updated recommendations on the use of the hepatitis B vaccine regarding target groups, immunization schedules, and storage and distribution.

Sign Up for Free e-newsletters